PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

Lei Li

Status: Unknown

Conditions: Objective Remission Rate; Immune Checkpoint Inhibitors; Anti-programmed Death-1 Antibody; Persistent Advanced Cervical Carcinoma; Overall Survival; Radiotherapy; Recurrent Cervical Carcinoma; Progression-free Survival; Metastatic Cervical Carcinoma; Severe Adverse Events

Treatments: Combination Product: Radiotherapy for targeted lesions and PD-1 antibody

Study type: Observational

Funder types: Other

Identifiers

NCT05310305

IMURADIO1

Details and patient eligibility

About

This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical carcinomas. Patients may or may not accept PD-1 antibody as maintenance therapy. Patients are followed up and the survival outcomes are evaluated. The primary endpoint are objective remission rate. The secondary endpoints are progression-free survival, overall survival and severe adverse events.

Enrollment: 20 estimated patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged 18 years or older
• Confirmed of recurrent, metastatic, and persistent advanced cervical cancer
• Confirmed of subtypes of cervical squamous carcinoma, adenocarcinoma and adenosquamous carcinoma
• Accepting radiotherapy with concurrent anti PD-1 therapy
• With detailed follow-up outcomes

Exclusion criteria

• Not meeting all of the inclusion criteria